TICKERNERD
Menu
INDVINDVHealthcare · Drug Manufacturers - Specialty & Generic

INDV Stock Forecast: Indivior Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$37
−6.60% on the day

The 6 Wall Street analysts covering Indivior Pharmaceuticals, Inc. hold a median 12-month price target of $50 — +33.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 1 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$4.7B
Ticker Nerd rank
96 / 100
Median analyst target
$50
Analysts covering
6
Total return, dividends reinvested
1W
−6.6%
1M
−6.1%
YTD
+4.2%
1Y
+77.5%
From 52W high
−10.7%
From 52W low
+76.1%
$21
$42
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

INDV stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Indivior Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
96 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
97
Momentum
97
Revisions
94
Value
91
Volatility
91
Growth
81
Issuance
51
Accruals
26
Size
24

Quality (97): The business earns solid, repeatable profits on what it owns.

Accruals (26): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (24): Larger than most of the companies we track — more scrutinised, less often mispriced.

The rank is the raw material. Whether the rules would actually own Indivior Pharmaceuticals, Inc. — and when they’d sell — is the membership.

Wall Street

INDV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on INDV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26INDVHigh $59Median $50Low $46

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $46Median $50High $59

The green dot is the last close — the median target sits +33.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
18 June 2026BarclaysInitiatesOverweight$46
18 June 2026BarclaysInitiatesOverweight—
12 Jan 2026HC Wainwright & Co.MaintainsBuy—
31 Oct 2025Piper SandlerReiteratesOverweight—
30 Oct 2025HC Wainwright & Co.MaintainsBuy—
27 Aug 2025Craig-HallumMaintainsBuy—
6 Aug 2025HC Wainwright & Co.InitiatesBuy—
22 July 2025JefferiesAssumesBuy$20
30 June 2025Craig-HallumMaintainsBuy—
6 Mar 2025Piper SandlerMaintainsOverweight—
25 Oct 2024Piper SandlerReiteratesOverweight—
11 Oct 2024Craig-HallumMaintainsBuy—
11 Oct 2024Piper SandlerReiteratesOverweight—
13 Sept 2024Piper SandlerReiteratesOverweight—
23 July 2024Piper SandlerInitiatesOverweight—
10 July 2024Craig-HallumMaintainsBuy—
3 Apr 2024Craig-HallumInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

INDV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+23.5%
Analysts raising
4
Analysts cutting
0
Fundamentals

Indivior Pharmaceuticals, Inc. (INDV) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
19.8×

Cheaper than 39% of US stocks

Price / sales
3.5×

Cheaper than 36% of US stocks

Price / book
−33.8×

Cheaper than 99% of US stocks

EV / EBITDA
11.0×

Cheaper than 35% of US stocks

Growth & margins
Revenue growth (YoY)
19.2%

Higher than 71% of US stocks

Earnings growth (YoY)
89.4%

Higher than 85% of US stocks

Gross margin
87.4%

Higher than 95% of US stocks

Operating margin
46.1%

Higher than 95% of US stocks

Net margin
19.5%

Higher than 82% of US stocks

Returns & dividend
Return on equity
−212.1%

Higher than 6% of US stocks

Return on assets
22.6%

Higher than 99% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

INDV vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
INDVIndivior Pharmaceuticals, Inc.$4.7B
96
KNSAKiniksa Pharmaceuticals International Plc$5.7B
98
AMRXAmneal Pharmaceuticals, Inc.$5.8B
76
HIMSHims & Hers Health, Inc.$6.3B
18
LNTHLantheus Holdings, Inc.$6.4B
93
LQDALiquidia Corp.$7.2B
87
ALKSAlkermes Plc$8.1B
57
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. INDV appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest INDV news & analysis

Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Revenue

Benzinga · 3 Aug 2026positive

Supernus Pharmaceuticals and Indivior agreed on Monday to combine through a tax-free, all-stock merger of equals, creating a central nervous system (CNS) biopharmaceutical company with the potential for $2 billion in revenue.

Why it matters — Indivior shareholders would care because the company is uniting with Supernus to form a larger CNS biopharmaceutical leader with combined revenue potential of $2 billion.

INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

Business Wire · 3 Aug 2026negative

Investor rights law firm Halper Sadeh LLC announced it is investigating the proposed merger between Indivior Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc., looking into whether Indivior shareholders are receiving a fair price. The firm noted that upon closing, Indivior shareholders would own approximately 56.5% of the combined company and invited shareholders to learn about their rights and options.

Why it matters — The investigation raises a question about whether the merger consideration adequately values Indivior shares, which is directly relevant to Indivior shareholders evaluating the deal.

Indivior Pharmaceuticals Inc. (INDV) Q2 Earnings and Revenues Beat Estimates

Zacks Investment Research · 3 Aug 2026positive

Indivior Pharmaceuticals reported Q2 earnings of $1.15 per share, above the Zacks Consensus Estimate of $0.97 per share and up from $0.51 per share a year earlier. The results reflect a quarterly earnings and revenue beat.

Why it matters — An INDV watcher would note that the company exceeded analyst expectations and showed year-over-year earnings growth in the quarter.

Supernus, Indivior merge to strengthen neuroscience drug portfolio

Reuters · 3 Aug 2026positive

Supernus Pharmaceuticals and Indivior Pharmaceuticals agreed on Monday to an all-stock merger that would create a company with about $2.2 billion in annual revenue and a portfolio of medicines for neurological, psychiatric and addiction-related conditions.

Why it matters — For an Indivior watcher, this confirms Indivior's planned combination with Supernus, which would broaden its drug portfolio and revenue base.

Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance

GlobeNewsWire · 3 Aug 2026positive

Indivior reported Q2 2026 results, with total net revenue of $343 million (up 14% year over year), record quarterly SUBLOCADE net revenue of $253 million (up 21%), record GAAP net income of $122 million, record non-GAAP net income of $142 million, and record adjusted EBITDA of $186 million (up 111%). The company repurchased about 4.7 million shares for $175 million in the quarter and raised its full-year 2026 financial guidance.

Why it matters — The record quarterly results, driven by growth in SUBLOCADE, and an upward revision to full-year 2026 guidance signal an improving earnings outlook for INDV.

FAQ

Frequently asked questions about INDV stock

What is the INDV stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Indivior Pharmaceuticals, Inc. have a median 12-month price target of $50, with estimates ranging from $46 to $59. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is INDV stock a buy right now?

Of the 6 analysts covering Indivior Pharmaceuticals, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Indivior Pharmaceuticals, Inc. 96 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank INDV?

As at 1 Aug 2026, Indivior Pharmaceuticals, Inc. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (97 of 100).

Will INDV stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +33.8% from the last close, and Ticker Nerd's factor model ranks Indivior Pharmaceuticals, Inc. 96 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the INDV stock forecast for 2030?

No analyst covering Indivior Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INDV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $46 to $59 over the next 12 months.

How has INDV stock performed over the past year?

Indivior Pharmaceuticals, Inc. returned +77.5% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Indivior Pharmaceuticals, Inc. do?

Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on treating substance use disorders and related mental health conditions.

What is the latest news on INDV?

The most recent item we track (Benzinga, 3 Aug 2026): "Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Revenue". Supernus Pharmaceuticals and Indivior agreed on Monday to combine through a tax-free, all-stock merger of equals, creating a central nervous system (CNS) biopharmaceutical company with the potential for $2 billion in revenue.

Company

About Indivior Pharmaceuticals, Inc.

Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on treating substance use disorders and related mental health conditions. The company concentrates on evidence-based therapies for opioid use disorder, including long-acting injectable and sublingual formulations designed to support adherence and sustained recovery. Its portfolio also extends to treatments addressing opioid overdose, alcohol dependence, and other addiction-related indications, positioning it as a key player in addiction medicine. Indivior Pharmaceuticals, Inc. integrates neuroscience, clinical research, and real-world data to develop and optimize therapies for chronic, relapsing conditions associated with substance use. The company works with healthcare providers, treatment centers, and public health systems, supplying products and clinical support across multiple regions. Founded in 1994 and headquartered in the United States, Indivior Pharmaceuticals, Inc. plays a significant role in the global effort to address opioid use disorder and other substance-related health burdens through specialized pharmacological treatments.

CEO Mr. Joseph J. Ciaffoni · 827 employees · United States · https://www.indivior.com